Clinical trials: Invasive Bladder Cancer
Survivors of Childhood Cancer, Bladder Dysfunction
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.
- Trial name
- NCT04993859
- Testing
- Non-invasive Urodynamic Test (niUDS), Urinary proteomic screen, Dysfunctional Voiding Symptom Score Survey (DVSS)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Colorado, Denver
Non Muscle Invasive Bladder Cancer
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
The goal of this clinical trial is to compare the efficacy and safety of two Bacillus Calmette-Guérin (BCG) substrains (RIVM and Russian) in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)…
- Trial name
- NCT06767982
- Testing
- Bacillus Calmette-Guerin (BCG)
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara University
Recurrent Superficial Bladder Cancer, Distilled Water
Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection
The purpose of this study is to compare and evaluate the efficacy of distilled water vs Mitomycin C on preventing the recurrences of intermediate risk group recurrent superficial bladder cancer administered as a single dose…
- Trial name
- NCT00816075
- Testing
- distilled water
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Bozyaka Training and Research Hospital
Bladder Cancer
Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer
Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis.
- Trial name
- NCT06092450
- Testing
- develop and validate a deep learning radiomics model based on preoperative enhanced CT image
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00080795
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Non-muscle Invasive Bladder Cancer
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
The aim is to evaluate and compare treatment strategies for non-muscle invasive bladder cancer. Furthermore, the impact of intravesical instillations on bladder function will be examined by urodynamic examination both prior to…
- Trial name
- URODYN (NCT04943094)
- Testing
- Urodynamic examination
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Prostate Cancer, Bladder Outlet Obstruction
Prostatic Artery Embolization in Advanced Prostate Cancer
This is a pilot study assessing efficacy and safety in patients with advanced prostate cancer.
- Trial name
- NCT03457805
- Testing
- Prostatic Artery Embolization
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Dominik Abt
Bladder Cancer, Urethral Cancer
Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003701
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- 13 sites in United States
- Volunteers
- 490 people
- Sponsor
- Eastern Cooperative Oncology Group
Bladder Cancer
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence (60 to 70%) and progression (20 to 30%) to muscle-invasive bladder cancer (MIBC).
- Trial name
- IMMUN VESSIE (NCT04726735)
- Testing
- Samples of bladder tissue
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux